
Strand Life Sciences has published the research behind its CancerSpot multi-cancer early detection test in the Proceedings of the National Academy of Sciences (PNAS). The four-year study used blood samples from 1,480 subjects and involved 43 hospitals across India.
The study found that in cancer patients, higher levels of circulating DNA were associated with stronger cancer-related signals, challenging the assumption that immune-cell DNA would dilute tumour contributions. On an independent validation cohort, CancerSpot demonstrated a false positive rate of 1.4 per cent and detected 72 per cent of cancers. Kalkine reports a tissue-of-origin accuracy of about 76 per cent, noted within the context of study design limitations.
Strand CEO Ramesh Hariharan said publication in PNAS attests to the rigour of the science. Dr Sewanti Limaye, a co-author, said the priority is translating the discovery into independently validated screening strategies.
Kalkine's article frames the CancerSpot publication as a preliminary scientific step, foregrounding caveats about clinical adoption and cost, while Express Healthcare leads with the milestone of PNAS publication and the key finding that immune-cell DNA does not dilute tumor signals. Kalkine omits the specificity and sensitivity figures that Express Healthcare reports (1.4% false positive rate, 72% detection), and Express Healthcare does not discuss false-positive trade-offs at population scale. The balanced reading is that peer-reviewed publication confirms scientific validity, but the studies cited report sensitivity and specificity in a research cohort, not in real-world screening. Both sources agree the next step is independent validation and translation to clinical practice, as Dr Limaye states.
Coverage: 2 sources, 2 neutral
Sources (2): kalkine.co.in (neutral report), expresshealthcare.in (neutral report)
This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Methodology and corrections.